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Abbreviations
and Acronyms
AF = atrial ﬁbrillation
AFL = atrial ﬂutter
CI = conﬁdence interval
CRT-D = cardiac
resynchronization therapy
deﬁbrillator
HR = hazard ratio
ICD = implantable
cardioverter-deﬁbrillator
MVT = monomorphic
ventricular tachycardia
PMVT = polymorphic
ventricular tachycardia
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1675Implantable cardioverter-deﬁbrillators (ICDs) and cardiac
resynchronization therapy deﬁbrillators (CRT-Ds) improve
survival in patients with congestive heart failure or ventric-
ular arrhythmias (1–3). However, 10% to 17% of patients
in primary prevention ICD and CRT-D trials receive
inappropriate or unnecessary shocks for sinus tachycardia,
supraventricular tachycardia (SVT), or atrial ﬁbrillation
(AF)/atrial ﬂutter (AFL) over the ﬁrst 2 to 4 years after
implant of the device (4–6). Some studies have shown that
not only do patients who receive appropriate shocks for
ventricular arrhythmias have an increased risk of death, but
those who receive inappropriate shocks also have an
increased risk of death compared with patients who do not
receive any shocks (4–6). It remains unknown if the
increased risk of death after inappropriate shocks is due to
potentially harmful effects of ICD shocks.See page 1680
SVT = supraventricular
tachycardia
VF = ventricular ﬁbrillation
VT = ventricular tachycardiaMany ICD and CRT-D devices are now followed remotely
from transmitters in patients’ homes. The data, including shock
and rhythm data, from ICD and CRT-D devices are trans-
mitted on a regular basis over a secure network to a central server.
This provides a unique opportunity to analyze data in a large
number of “real-world” ICD and CRT-D recipients.
We sought to determine if decreased survival after inap-
propriate shocks is due to the underlying arrhythmia or the
ICD shock itself.Methods
Study design and subject participation. The ALTITUDE
project is a clinical science initiative formed to prospectively
analyze data from ICD and CRT-D devices followed on
a remote monitoring system (LATITUDE, Boston Scien-
tiﬁc Corp., Natick, Massachusetts). The ALTITUDE study
group consists of an independent physician leadership panel
that prospectively identiﬁes key clinical questions for anal-
ysis. De-identiﬁed patient data from the remote monitoring
system were analyzed for this study.
At the time of this analysis, 127,134 patients with an ICD
and a CRT-D from 1,550 centers across the United States
were being followed on the LATITUDE remote monitoring
system. A total of 28,398 patients received 1 or more ICD or
CRT-D shock therapies. A random sample of 3,809 patients
(13.4%) who experienced 1 or more spontaneous deﬁbrillator
shocks was evaluated. Patients were drawn from 2 previous
studies of adjudicated shocked episodes (6,7). In the ﬁrst
study, a random sample of 2,000 patients who received ICD
or CRT-D shocks was included. In the second study, 1,809
patients were randomly sampled from groups of patients
based on ICD or CRT-D tachyarrhythmia therapy pro-
gramming parameters. Further details regarding patient
sampling can be found in the 2 studies referenced.
A physician panel of 7 board-certiﬁed cardiac electro-
physiologists adjudicated the rhythm at the time of the shockepisodes by reviewing the intra-
cardiac electrograms stored in the
ICDor CRT-Ddevice at the time
of therapy.Themethods for review
of the electrograms and level of
agreement have been previously
reported (8).
Survival status was obtained by
cross-reference to the U.S. Social
Security Death Index. Follow-up
for vital status data was continued
for 12 months after collection of
study data was closed to allow for
lag time in reporting. Patients
without Social Security numbers
were excluded from the analysis
and totaled 5% of the study
population.
We sought to compare survival
in patients experiencing a shock
by underlying rhythm at the time
of shock and survival in patients with and without a shock.
Two methods of analysis were pre-speciﬁed: analysis of time
from ﬁrst shock to death by adjudicated rhythm and matched
pair analysis of patients with a shock to patients without
a shock.
Statistical methods. ANALYSIS OF TIME FROM FIRST SHOCK
TODEATH. The ﬁrst adjudicated episode for each patient was
included in the analysis. Patients were grouped by adjudi-
cated rhythm observed at the time of the ﬁrst shock episode.
Categories for rhythm classiﬁcation were ventricular ﬁbril-
lation (VF)/polymorphic ventricular tachycardia (PMVT),
monomorphic ventricular tachycardia (MVT), MVT and
PMVT, AF/AFL, sinus tachycardia, SVT, nonsustained
arrhythmia, and shock secondary to noise, artifact, or over-
sensing. Nonsustained arrhythmias were deﬁned as arrhyth-
mias that met device detection criteria and resulted in a shock
but the arrhythmia terminated spontaneously before delivery
of the shock. Kaplan-Meier and Cox proportional hazards
model analyses were performed for time from ﬁrst shock to
death. Patients were grouped by adjudicated rhythm that
resulted in the ﬁrst shock, accounting for left truncation at
the ﬁrst LATITUDE transmission with a common censor
date of January 1, 2010, to allow for complete reporting of
mortality information. Cox model covariates were adjusted
for age at implant and sex.
MATCHED PAIR ANALYSIS. For each patient with an adjudi-
cated shock, a matching patient was identiﬁed who was
known to be shock-free through the point in time when the
adjudicated shock was delivered (n = 3,630). Patients
were matched by age at implant, sex, device type (ICD or
CRT-D), implant year, and time from implant to ﬁrst remote
monitoring transmission (in quarter years). In the matched
analysis, 95.3% of patients with a shock were included. Each
pair was categorized by one of 4 outcomes: shock patient
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1676died, matched patient died, both died, or neither died.
Analysis was performed independently for each adjudication
category to assess the association between shock occurrence
and mortality. The Cochran-Mantel-Haenszel test was used
to test for homogeneity of effect across patients and time. An
overall odds ratio was calculated using the Mantel-Haenszel
estimator. All analyses were performed using SAS version
9.2 (SAS Institute Inc., Cary, North Carolina).Results
Patients were followed up for an average of 3.1  1.7 years
after implant and 2.1  0.4 years after a ﬁrst shock. The
mean age of the study group was 64  13 years, and 78%
were male. Patients with a CRT-D were older than patients
with an ICD (Table 1), but there was no signiﬁcant differ-
ence in age or sex between single-chamber and dual-chamber
ICD groups. Of the 3,809 patients in the study group, 950
(24.9%) had a single-chamber ICD, 1,318 (34.6%) had
a dual-chamber ICD, and 1,541 (40.5%) had a CRT-D
device. Unsuccessful antitachycardia pacing preceded the
ﬁrst shock in 1,118 patients (29.4%). Patient characteristics
and the adjudicated rhythm that triggered the shock are
shown in Table 1.
Rhythm at time of ﬁrst shock. Of the ﬁrst shock episodes,
58.7% were appropriate shocks for sustained ventricular
arrhythmias and 41.3% were inappropriate shocks for non-
ventricular arrhythmias. Sustained MVT was the most com-
mon rhythm that led to a shock in this cohort, accounting
for 36% of ﬁrst shocks. VF/PMVT (16%) was the next
most frequent ventricular rhythm, followed by PMVT and
MVT (7%). The most common reason for an inappropriate
shock was AF/AFL, which accounted for 18% of all ﬁrst
shocks. This was followed closely by sinus tachycardia or
SVT, which accounted for 17% of episodes. Arrhythmias
adjudicated as nonsustained ventricular tachycardia (VT)
accounted for 1.4% of ﬁrst shocks, and nonarrhythmic
events (noise/artifact/oversensing) accounted for 5%. Patient
demographics and rhythm at the time of ﬁrst shock wereTable 1 Demographics and Distribution of Adjudicated First Shocks
Variable Overall Cardiac Res
Age (yrs) 64.1  13.3 (3,809)
(1.0, 91.0)
Male 78.2% (2,977/3,809)
Rhythm type
VF/polymorphic VT 16.1% (614/3,809)
Monomorphic VT 36.0% (1,372/3,809)
Polymorphic and monomorphic VT 6.6% (253/3,809)
Atrial ﬁbrillation/atrial ﬂutter 18.2% (694/3,809)
Sinus tachycardia or SVT 16.9% (645/3,809)
Nonsustained arrhythmia 1.4% (53/3,809)
Noise/artifact/oversensing 4.7% (178/3,809)
Values are %  SD (n) (minimum, maximum) or % (n/N).
SVT ¼ supraventricular tachycardia; VF ¼ ventricular ﬁbrillation; VT ¼ ventricular tachycardia.similar between the patient populations sampled from the
2 previous studies (Table 1).
Survival by rhythm at time of ﬁrst shock. Patients who
received a ﬁrst shock for a ventricular arrhythmia had an
increased risk of death during follow-up compared with
those who received a ﬁrst shock for a nonventricular
arrhythmia (Fig. 1). Compared with patients with an ICD
who received a shock for MVT, those who received a shock
for PMVT or VF had an increased risk of death (hazard
ratio [HR] for death: 1.35; 95% conﬁdence interval [CI]:
1.01 to 1.81). In contrast, there was no signiﬁcant difference
in survival in patients with a CRT-D who received a shock
for VF/PMVT compared with MVT (HR for death: 0.99;
95% CI: 0.78 to 1.28). Compared with MVT, there was
a decreased risk of death during follow-up in those who
received a ﬁrst shock for sinus tachycardia/SVT (HR for
death: 0.60; 95% CI: 0.47 to 0.76) or noise/artifact/over-
sensing (HR for death: 0.49; 95% CI: 0.33 to 0.73), while
there was no signiﬁcant difference for AF/AFL (HR for
death: 0.84; 95% CI: 0.69 to 1.03). These results were
similar for both patients with an ICD and patients with
a CRT-D.
Table 2 details the type of rhythm at the time of
subsequent shocks for the 1,982 patients who had data
available on adjudicated episodes of subsequent shocks.
Most patients with an appropriate shock as their ﬁrst shock
had a combination of both appropriate and inappropriate
subsequent shocks (86.1% of patients with an appropriate
shock as their ﬁrst shock). In contrast, 72.2% of patients
who had an inappropriate shock as their ﬁrst shock only
had inappropriate shocks as subsequent shocks during the
study period.
Matched comparison to no-shock group. The number of
patients matched by adjudicated rhythm and number of
deaths in the matched analysis are shown in Table 3. Within
each rhythm group, the time of follow-up was not different
between the shock group and no-shock group (p ¼ NS).
There was an increased risk of death during follow-up in
patients who received an appropriate shock (HR: 2.82; 95%ynchronization Therapy Deﬁbrillator Implantable Cardioverter-Deﬁbrillator
66.9  11.7 (1,541)
(24.0, 90.0)
62.2  14.0 (2,268)
(1.0, 91.0)
79.2% (1,221/1,541) 77.4% (1,756/2,268)
16.7% (257/1,541) 15.7% (357/2,268)
37.2% (573/1,541) 35.2% (799/2,268)
6.9% (106/1,541) 6.5% (147/2,268)
15.9% (245/1,541) 19.8% (449/2,268)
16.2% (249/1,541) 17.5% (396/2,268)
1.0% (16/1,541) 1.6% (37/2,268)
6.2% (95/1,541) 3.7% (83/2,268)
Figure 1 Survival Based on Rhythm Shocked
Survival after ﬁrst shock based on rhythm that resulted in the shock. AF/AFlutter ¼
atrial ﬁbrillation/atrial ﬂutter; SVT ¼ supraventricular tachycardia; VT/VF ¼
ventricular tachycardia/ventricular ﬁbrillation.
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1677CI: 2.46 to 3.24) or inappropriate shock (HR: 1.81; 95%
CI: 1.53 to 2.13) compared with a matched group who did
not receive a shock. Compared with patients without a
shock, patients with a shock had an increased risk of death
if the shock was for a ventricular arrhythmia (HR: 2.10; 95%
CI: 1.54 to 2.86 for VF/PMVT; p < 0.0001) or AF/AFL
(HR: 1.61; 95% CI: 1.17 to 2.21; p ¼ 0.003) (Fig. 2).
However, there was no signiﬁcant difference in survival for
patients who received a shock for sinus tachycardia/SVT
(HR: 0.97; 95% CI: 0.68 to 1.37; p ¼ 0.86), noise/artifact/
oversensing (HR: 0.91; 95% CI: 0.50 to 1.67; p ¼ 0.76), or
nonsustained arrhythmias (HR: 2.17; 95% CI: 0.86 to 5.70;
p ¼ 0.11) compared with the no-shock group. For patients
who received an inappropriate shock, only shocks for
AF/AFL were associated with an increased risk of death.
The number of patients in the nonsustained arrhythmia
group was small, resulting in large CIs that overlapped with
the HRs for other groups.
Discussion
Patients with an ICD or CRT-D who receive an appropriate
or inappropriate shock have an increased risk of death
compared with those who did not receive a shock. TheTable 2 Rhythm During Subsequent Shocks Cate
First Shock
Appropriate 58.0% (1,150/1,982)
Inappropriate 42.0% (832/1,982)
Values are % (n/N).
Appropriate ¼ ventricular arrhythmia; Inappropriate ¼ nonventricular arrhy
shock.primary ﬁnding of this study is that the risk associated with
inappropriate shock is limited to those receiving shocks for
AF/AFL. Those who received an inappropriate shock for
“benign rhythms” (sinus tachycardia or SVT) or non-
arrhythmia events (noise, artifact, and oversensing) had
similar survival to those who did not receive a shock. These
data suggest that increased long-term mortality after a shock
is due to the underlying arrhythmia as opposed to the shock
itself.
Previous studies have shown an increased risk of death in
patients who receive inappropriate shocks compared with
those without a shock. The SCD-HeFT (Sudden Cardiac
Death in Heart Failure Trial) found that in patients who
survived more than 24 h after a shock, there was an increased
risk of death whether shocks were appropriate (HR: 3.0) or
inappropriate (HR: 1.6) (5). The rate of survival more than
24 h after initial shock is similar to that in our study, in
which patients had to survive their ﬁrst shock for data to be
transmitted via the ICD home remote monitoring system
and be included in the study. In a previous ALTITUDE
study, we reported an increased risk of death after appro-
priate or inappropriate shocks compared with patients who
never received a shock (6). This current study provides more
detailed insight into survival based on the underlying rhythm
at the time of an ICD shock. This allowed us to evaluate the
association between survival after inappropriate shocks for
atrial arrhythmias and survival after inappropriate shocks
triggered by “benign” conditions (noise, artifact, and over-
sensing). The increased risk of death after inappropriate
shocks reported in previous studies raised the question if the
ICD shock itself may cause enough harm to increase
a patient’s risk of death. There are studies on animals and
a small number of patients suggesting that markers of
myocardial damage increase after high-energy shocks for
termination of VF (9,10). However, the effect of myocardial
damage and cardiac output after a transthoracic shock during
normal sinus rhythm varies by patient (11). Whether or not
a small degree of myocardial injury can affect a patient’s
survival has been debated. The ﬁndings of our study provide
new evidence to support the concept that the ICD shock
itself does not increase the risk of death.
The recent MADIT-RIT (Multicenter Automatic Deﬁ-
brillator Implantation Trial–Reduce Inappropriate Therapy)
study found that conventional ICD detection and therapygorized by Rhythm at Time of First Shock
Subsequent Shocks
Appropriate 10.3% (65/632)
Inappropriate 3.6% (23/632)
Both 86.1% (544/632)
Appropriate 18.3% (66/360)
Inappropriate 72.2% (260/360)
Both 9.4% (34/360)
thmia; Both ¼ both appropriate and inappropriate shocks after the ﬁrst
Table 3
Comparison of Mortality in Patients Who Received Shocks, Categorized by Rhythm at the Time of Shock,
Compared With a Matched Group of Patients Who Did Not Receive a Shock
Variable Original Count Matched Count
No. of Deaths
No-Shock Group Shock Group
VF/polymorphic VT 614 579 14.0% (81/579) 25.4% (147/579)
Monomorphic VT 1,372 1,319 17.6% (232/1,319) 25.7% (339/1,319)
Polymorphic and monomorphic VT 253 245 12.7% (31/245) 28.6% (70/245)
Atrial ﬁbrillation and ﬂutter 694 667 13.3% (89/667) 19.0% (127/667)
Sinus tachycardia or SVT 645 603 13.3% (80/603) 12.9% (78/603)
Nonsustained arrhythmia 53 50 16.0% (8/50) 30.0% (15/50)
Noise/artifact/oversensing 178 167 16.8% (28/167) 15.6% (26/167)
Values are n or % (n/N). Mean follow-up was 3 years.
Abbreviations as in Table 1.
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and increased mortality (12). Does this contradict the ﬁnd-
ings of our study? There are a couple of key differences
in the 2 studies. The increase in ﬁrst ICD therapies with
conventional programming in MADIT-RIT compared with
high-rate therapy and delayed therapy groups was primarily
due to increased episodes of antitachycardia pacing, while
ﬁrst shock episodes were not signiﬁcantly different between
groups. This suggests that unnecessary antitachycardia pacing
increases mortality, possibly due to induction of ventricular
arrhythmias. Our study was limited to patients who received
ICD shocks, not antitachycardia pacing therapy alone. In
addition, the survival analysis in MADIT-RIT included
deaths during or immediately after the ﬁrst ICD therapy.
Our study looked at the long-term effects of an inappropriate
ICD shock in patients who survived the initial ICD shock.
Combining the results of the 2 studies, it could be concluded
that unnecessary antitachycardia pacing may increase mor-
tality, whereas unnecessary shocks for sinus tachycardia,
SVT, or noise/artifact/oversensing do not appear to affect
long-term survival.
Why was AF/AFL the only nonventricular arrhythmia
associated with increased mortality after a shock? Some
population studies have demonstrated an association between
AF and increased mortality, regardless of the presence or
absence of an ICD shock (13–16). The increased risk ofFigure 2 Risk of Death After First Shock Compared With No-Shock M
Mantel-Haenszel odds ratio of death after ﬁrst shock based on the rhythm that resulted
shocks for atrial ﬁbrillation or atrial ﬂutter were associated with an increased risk of death
MVT ¼ monomorphic ventricular tachycardia; NSVT ¼ nonsustained ventricular tachycard
VF ¼ ventricular ﬁbrillation.death in patients who receive an ICD shock for AF is most
likely secondary to the underlying substrate and comorbid-
ities associated with AF. Receiving a shock due to rapid
ventricular rates in the setting of AF/AFL may be a marker
for patients of inadequate doses of beta-blocker medications
or indicate that atrioventricular nodal blockade is inadequate
in the setting of sympathetic activation associated with
worsening heart failure. Rapid ventricular rates may lead to
worsening ventricular function and heart failure. In addition,
some patients convert to sinus rhythm with an ICD shock. If
they are not on anticoagulation therapy at the time of
conversion, there may be an increased risk of stroke or other
thromboembolic event. This may contribute to an increased
risk for death after a shock.
Analyses of pooled study data have found that patients
with shock therapy for VT/VF have higher rates of mortality
than patients with VT/VF terminated by antitachycardia
pacing therapy (17). However, ventricular arrhythmias are
triggered by various mechanisms. VF/PMVT is more likely
than MVT to be triggered by acute myocardial ischemia or
infarction (17,18). VF/PMVT is unlikely to terminate with
antitachycardia pacing, thus necessitating an ICD shock for
termination. In contrast, MVT is more likely to terminate
with antitachycardia pacing (19). MVT can be triggered
by a simple premature ventricular contraction or couplet
without more serious coexisting circumstances. This mayatched Group
in the shock. The last 3 rhythm categories are inappropriate shocks. Of these, only
compared with no-shock matched controls. Data are presented in a log axis format.
ia; PMVT ¼ polymorphic ventricular tachycardia; SVT ¼ supraventricular tachycardia;
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1679result in an association between ventricular arrhythmias that
require shocks and coexisting conditions that trigger shocks
(i.e., myocardial ischemia or acute infarction). This makes
it difﬁcult to uncouple the type of ICD therapy for the
ventricular arrhythmia from the underlying coexisting
cardiac state. Patients with ventricular rhythms may be more
susceptible to a small degree of myocardial injury from
a shock compared with patients who receive a shock for
a nonventricular arrhythmia (5,20). In a recent single-center
study, induced arrhythmias have also been compared with
shocks for VT/VF and were not associated with an increased
risk of mortality. This implicates the coexisting conditions at
the time of the arrhythmia rather than the shock (21).
Study limitations. The limitations of this study include
limited available clinical data regarding patient comorbidities
to allow for further adjusted analysis. No data were available
on patient medications. This also limited the matching
process to patient age, sex, device type, year of implant, and
time from implant to ﬁrst remote transmission. Devices were
from a single manufacturer and limited to patients enrolled
in a remote monitoring system. Patients had to survive their
ﬁrst ICD shock to perform a subsequent remote trans-
mission and be included in this study. As a result, this study
analyzed the long-term survival of patients who survived
their ﬁrst shock.
Conclusions
Compared with no shock, those who received a ﬁrst shock
for ventricular arrhythmia or AF had an increased risk of
death. There was no signiﬁcant difference in survival after an
inappropriate shock for sinus tachycardia/SVT or noise/
artifact/oversensing compared with no shock. In this study,
the adverse prognosis after shock therapy is more related to
the underlying arrhythmia than to a long-term adverse effect
from the shock itself.
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